CR7859A - Sales Fumarato Cristalinas de Furo (2,3-c) Piridinilcarboxamida sustituida con 1-Azabiciclo (2.2.2) octilo y composiciones y preparaciones de las mismas - Google Patents

Sales Fumarato Cristalinas de Furo (2,3-c) Piridinilcarboxamida sustituida con 1-Azabiciclo (2.2.2) octilo y composiciones y preparaciones de las mismas

Info

Publication number
CR7859A
CR7859A CR7859A CR7859A CR7859A CR 7859 A CR7859 A CR 7859A CR 7859 A CR7859 A CR 7859A CR 7859 A CR7859 A CR 7859A CR 7859 A CR7859 A CR 7859A
Authority
CR
Costa Rica
Prior art keywords
furo
azabicyclo
compositions
pyridinylcarboxamide
octyl
Prior art date
Application number
CR7859A
Other languages
English (en)
Inventor
Yahya Sheikh Ahmad
Gordon Selbo John
D Hewitt Bradley
Warner Rappath David
Gregory Wishka Donn
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of CR7859A publication Critical patent/CR7859A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C07D453/04—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems having a quinolyl-4, a substituted quinolyl-4 or a alkylenedioxy-quinolyl-4 radical linked through only one carbon atom, attached in position 2, e.g. quinine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invencion proporciona sales fumarato de N-[1-azabiciclo[2.2.2]oct-3-il]furo[2,3-c]piridin-5-carboxamida, composiciones, mezclas racemicas o enantiomeros puros de las mismas, y la preparacion de las mismas.Las sales fumarato son utiles para tratar enfermedades o afecciones en los que se sabe que esta implicado a7.
CR7859A 2002-12-06 2005-06-06 Sales Fumarato Cristalinas de Furo (2,3-c) Piridinilcarboxamida sustituida con 1-Azabiciclo (2.2.2) octilo y composiciones y preparaciones de las mismas CR7859A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43161902P 2002-12-06 2002-12-06

Publications (1)

Publication Number Publication Date
CR7859A true CR7859A (es) 2005-07-08

Family

ID=32507764

Family Applications (1)

Application Number Title Priority Date Filing Date
CR7859A CR7859A (es) 2002-12-06 2005-06-06 Sales Fumarato Cristalinas de Furo (2,3-c) Piridinilcarboxamida sustituida con 1-Azabiciclo (2.2.2) octilo y composiciones y preparaciones de las mismas

Country Status (22)

Country Link
US (1) US20050165047A1 (es)
EP (1) EP1572700A1 (es)
JP (1) JP2006510664A (es)
KR (1) KR20050087826A (es)
CN (1) CN1720248A (es)
AR (1) AR042295A1 (es)
AU (1) AU2003302911A1 (es)
BR (1) BR0317019A (es)
CA (1) CA2506529A1 (es)
CR (1) CR7859A (es)
EA (1) EA200500738A1 (es)
EC (1) ECSP055834A (es)
HR (1) HRP20050494A2 (es)
IS (1) IS7844A (es)
MA (1) MA27604A1 (es)
MX (1) MXPA05005943A (es)
NO (1) NO20052560L (es)
OA (1) OA12968A (es)
PL (1) PL377052A1 (es)
TW (1) TW200427691A (es)
WO (1) WO2004052894A1 (es)
ZA (1) ZA200503988B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6670178B1 (en) 1992-07-10 2003-12-30 Transkaryotic Therapies, Inc. In Vivo production and delivery of insulinotropin for gene therapy
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2254598B1 (en) * 2008-02-13 2013-07-10 Targacept, Inc. Combination of alpha 7 nicotinic agonists and antipsychotics
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
TWI519532B (zh) 2010-05-17 2016-02-01 艾維沃製藥公司 （Ｒ）－７－氯－Ｎ－（啶－３－基）苯並［b］噻吩－２－羧醯胺鹽酸鹽單水合物之結晶形體
RU2017136693A (ru) 2012-05-08 2019-02-08 Форум Фармасьютикалз, Инк. Способы поддержания, лечения или улучшения когнитивной функции

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988002751A1 (fr) * 1986-10-13 1988-04-21 Asahi Kasei Kogyo Kabushiki Kaisha Derives de pyridine
AR036040A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen

Also Published As

Publication number Publication date
TW200427691A (en) 2004-12-16
BR0317019A (pt) 2005-10-25
CN1720248A (zh) 2006-01-11
NO20052560D0 (no) 2005-05-26
US20050165047A1 (en) 2005-07-28
NO20052560L (no) 2005-08-17
AU2003302911A1 (en) 2004-06-30
MXPA05005943A (es) 2005-08-18
JP2006510664A (ja) 2006-03-30
OA12968A (en) 2006-10-13
IS7844A (is) 2005-05-12
KR20050087826A (ko) 2005-08-31
WO2004052894A1 (en) 2004-06-24
CA2506529A1 (en) 2004-06-24
EP1572700A1 (en) 2005-09-14
AR042295A1 (es) 2005-06-15
MA27604A1 (fr) 2005-11-01
HRP20050494A2 (en) 2005-10-31
PL377052A1 (pl) 2006-01-23
EA200500738A1 (ru) 2005-12-29
ZA200503988B (en) 2006-09-27
ECSP055834A (es) 2005-08-11

Similar Documents

Publication Publication Date Title
NO2020010I1 (no) fostamatinib eller et farmasøytisk akseptabelt salt av fostamatinib, eller et hydrat, solvat eller N-oksid av fostamatinib eller det farmasøytisk akseptable saltet av fostamatinib, spesielt fostamatinib dinatrium, eventuelt på form av et hydrat
PA8537501A1 (es) Naftostirilos
NO20034056D0 (no) Proliferative sykdommer
AR013477A1 (es) Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp.
DE602004006536D1 (de) Bekämpfng von parasiten in tieren durch anwendung von imidazoä1,2-büpyridazinderivaten
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
GT200500007A (es) [1,8]naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia.
PA8586401A1 (es) 4-piperazinilbencenosulfonilindoles y uso de los mismos
CR7332A (es) INHIBIDORES DEL FACTOR Xa Y DE OTRAS PROTEASAS DE SERINA IMPLICADAS EN LA CASCADA DE LA COAGULACION
LU92433I2 (fr) Olodatérol, ses isomères optiques individuels, mélanges d'énantiomères individuels ou de racémates, ses sels d'addition d'acide avec des acides pharmaceutiquement acceptables, ainsi que ses solvates et/ou ses hydrates, en particulier l'olodatérol et le chlorhydrate d'olodatérol
HN2002000154A (es) Azaindoles
NO330934B1 (no) Flytende farmasoytisk preparat samt anvendelse og fremstilling derav.
CO5160262A1 (es) Formulaciones farmaceuticas de liberacion controlada
CL2007002450A1 (es) Forma polimorfica i del enantiomero levogiro o dextrogiro de modafinilo; su procedimiento de preparacion; y composicion farmaceutica que los comprende (divisional solicitud 2693-03).
PA8621901A1 (es) Derivados de sulfonamida para el tratamiento de enfermedades
DK1747220T3 (da) Substituerede 1H-pyrrolo[3,2-B, 3,2-C og 2,3-C]pyridin-2-carboxamider og relaterede analoger som inhibitorer af casein kinase I epsilon
SV2004001481A (es) Derivados de nicotinamida utiles como inhibidores de pde4" ref. pc22065a
AR013079A1 (es) Derivados sustituidos de tetrahidrofurano-3-onas, de tetrahidropirano-3- onas y tetrahidrotiofen-3-onas, un procedimiento para su preparacion unacomposicion farmaceutica de un medicamento util como inhibidores de proteasas e intermediarios
HN2002000365A (es) Lactamas como antagonistas de taquiquininas
AR012193A1 (es) Nuevas combinaciones terapeuticas
ATE374043T1 (de) Stabilisierte zusammensetzungen mit einem therapeutischen wirkstoff; zitronensäure oder einer konjugierten base und chlordioxid
ES2093782T3 (es) Piridazindionas y su uso en el tratamiento de trastornos neurologicos.
ES2147427T3 (es) Aminas ciclicas n-sustituidas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen.
ECSP055834A (es) SALES FUMARATO CRISTALINAS DE FURO[2,3-c]PIRIDINILCARBOXAMIDA SUSTITUIDA CON 1-AZABICICLO[2.2.2]OCTILO Y COMPOSICIONES Y PREPARACIONES DE LAS MISMAS
BR0208961A (pt) Composição farmacêutica demonstrando atividade anti-tumor, método para fabricar a mesma, e uso de uma tolueno sulfonamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)